United States Patent 12,122,789 (Drug Patent): Scope, Claim Coverage, and US Patent Landscape for Crystalline Form A Defined by XRPD Peaks
What is the scope of US Patent 12,122,789 and what do the claims actually cover?
Answer (scope in one line): US 12,122,789 claims crystalline Form A of a compound of formula (I), where Form A is defined by specific XRPD peak locations (Cu Kα option), plus optional corroborating IR and Raman spectral peaks, and downstream protection extends to pharmaceutical compositions and a kit.
Core invention framing
The independent claim (Claim 1) is a solid-form claim. It does not claim a process for making the solid form. It also does not claim a specific therapeutic use (at least in the provided claims). Instead, it claims identity of a crystalline polymorph by a spectral/solid-state fingerprint.
What “compound of formula (I)” means for claim coverage
The claims you provided are “technology-agnostic” with respect to the identity of the molecule because the chemical structure is not reproduced in the prompt. Patent scope therefore turns on:
- whether “formula (I)” in the patent corresponds to the marketed API (or a moiety protected by the patent estate); and
- whether competitors’ solids are the same polymorph (Form A) or a different solid form.
Practically, for infringement risk, the claim is about whether the accused solid form’s diffraction pattern matches the defined Form A XRPD set within the stated tolerances.
Which XRPD peaks define crystalline Form A under US 12,122,789?
Answer: Form A is defined by XRPD peaks selected from a fixed menu of 2θ values with ±0.2° tolerance. Claim 1 requires at least two peaks from the set; dependent claims tighten to three or more and also include alternative “pattern subsets.”
Claim 1: minimum XRPD match (at least two peaks)
Claim 1 recites Form A where XRPD comprises at least two peaks selected from:
- 8.3 (±0.2)
- 11.4 (±0.2)
- 15.1 (±0.2)
- 15.9 (±0.2)
- 17.0 (±0.2)
- 24.0 (±0.2)
- 25.6 (±0.2)
Claim meaning: A product is within the claim if its XRPD contains any combination of at least two of these peaks, regardless of the presence of additional peaks (the claim does not state “consists of”).
Claim 2: at least three peaks from the same menu
Claim 2 tightens Claim 1 to at least three peaks selected from:
- 8.3, 11.4, 15.1, 15.9, 17.0, 24.0, 25.6 (each ±0.2°)
Claim 12 to 15: fixed-super-set patterns anchored at 8.3
Claims 12–15 specify:
- an XRPD peak at 8.3 (±0.2) plus
- at least two / three / four / five additional peaks from {11.4, 15.1, 15.9, 17.0, 24.0, 25.6}
This materially increases enforceability against challengers that show the 8.3 peak.
Claim 16–20 and 21: narrower subsets that omit 8.3
Claims 16–20 recite Form A XRPD patterns with only certain peaks:
- Claim 16: 12.7 + 24.0 + 25.6
- Claim 17: 11.4 + 12.7 + 15.9 + 24.0 + 25.6
- Claim 18: 11.4 + 15.1 + 25.6
- Claim 19: 15.1 + 17.0 + 25.6
- Claim 20: 15.1 + 24.0 + 25.6
Claim 21 enumerates multi-peak alternatives for 8.3 paired with:
- 11.4 OR 15.1 OR 15.9 OR 17.0 (as alternative two-peak sets).
Claims 4 and 5: “extended fingerprint” lists (subsets with more peaks)
Claims 4 and 5 are not framed as “at least N peaks from a menu.” Instead, they specify particular peak positions and large peak lists.
- Claim 4: XRPD includes peaks at 8.3, 11.4, 12.7, 13.0, 15.1, 15.9, 17.0, 19.7, 22.4, 24.0, 25.6.
- Claim 5: XRPD includes a much larger list including (among others) 8.3, 11.4, 12.7, 13.0, 15.1, 15.4, 15.9, 16.7, 17.0, 17.5, 18.7, 19.4, 19.7, 19.8, 21.3, 22.4, 23.6, 24.0, 24.7, 25.6, 26.7, 26.8, 27.4, 29.3, 30.7.
Practical impact: These dependent claims substantially narrow the set of XRPD profiles covered, but they also provide strong fallback coverage if an infringing Form A exhibits the full/major peaks in the lists.
Cu Kα specificity (Claims 3, 22, 23)
- Claim 3: XRPD obtained from Cu Kα source.
- Claims 22 and 23: same limitation tied to claims 12 and 21.
Infringement implication: If an accused lab uses a different radiation source, it may attempt to design around these dependent claims. Claim 1/2 and most others are not expressly limited to Cu Kα in the text you provided, so the independent “menu peak” claims may still be asserted depending on whether the XRPD peak positions map consistently across instrument setups.
How do IR and Raman claims broaden or tighten protection?
Answer: The patent adds corroborating spectral constraints in dependent claims, which can help differentiate Form A from other polymorphs that share partial XRPD similarities.
IR spectrum (Claims 6 and 30)
- Claim 6: Form A has at least one IR peak at one of: 848 (±2), 885 (±2), 939 (±2), 1218 (±2) cm−1.
- Claim 30: requires at least three IR peaks from the same set.
Raman spectrum (Claims 7 and 31)
- Claim 7: Form A has at least one Raman peak at one of: 213 (±2), 257 (±2), 1061 (±2), 1570 (±2) cm−1.
- Claim 31: requires at least three Raman peaks from the same set.
Practical impact: IR/Raman claims are usually used to strengthen “is it really Form A?” evidentiary support. If the competitor’s XRPD is ambiguous, IR/Raman can pin the polymorph identity. Conversely, if a competitor alters crystallization conditions to produce a distinct polymorph with overlapping XRPD peaks, these spectral claims can tighten defense.
What do the pharmaceutical composition and kit claims cover?
Answer: The patent extends protection from the solid form to compositions comprising that Form A, including at least one oral aqueous constitution kit.
Composition claims (Claims 9, 10, 24–29)
- Claim 9: Pharmaceutical composition containing solid form of Claim 1 + pharmaceutically acceptable excipient.
- Claim 10: Composition of Claim 9 in powder form.
- Claims 24–29: additional composition claims tied to solid forms in Claims 12, 13, 14, 15, and 21.
Scope: Once Form A is established, these claims typically cover finished dosage-ready solids (powders) and formulations incorporating the polymorph.
Kit claim (Claim 11)
- Claim 11: kit comprising composition of Claim 9 and water as solvent to constitution into an oral aqueous solution.
Scope: A two-component kit where powder constitutes into solution with provided water.
What does the melting point claim add?
Answer: Dependent Claim 8 recites a thermal identity constraint: melting point above 298°C measured by DSC at 10 K/min.
- Claim 8: Form A has melting point > 298°C using DSC, heating rate 10 K/min.
Enforcement utility: Thermal data can distinguish Form A from related solids that may share similar XRPD peak sets but differ in stability or melting behavior.
How strong is patent coverage given the claim structure (menu-based XRPD vs exact fingerprints)?
Answer: The claim strategy has both breadth and fallback tiers.
Broad capture (breadth anchor)
- Claim 1 and Claim 2 are broad menu-based: any combination of at least two (or three) peaks from the defined set.
This makes design-around harder if competitor XRPD still shows multiple anchor peaks.
Narrow capture (fallback)
- Claims 4, 5, 12–21 enumerate specific peak sets anchored to 8.3 or other specific combinations.
- Claims 6/7/30/31 add IR/Raman checks.
- Claim 8 adds DSC melting threshold.
Resulting enforcement pattern: In litigation, plaintiffs typically assert broadest independent claim first (Claims 1/2) with fallback to multiple dependent claims depending on what the accused product’s solid-state data show.
What patents likely coexist in the same estate for this compound family?
Answer: The provided text alone does not identify the API name, assignees, filing dates, or related families. Without those, no defensible US/WO/EP landscape for “this compound” can be enumerated.
Under standard solid-form strategies, polymorph families like this often sit alongside:
- earlier composition or core compound patents (compound of formula (I));
- other polymorph form claims (Form B, hydrate/solvate forms);
- manufacturing/strain or crystallization process patents; and
- additional formulation patents (particle size, coatings, oral delivery systems).
But enumerating specific US patent numbers for those would require the missing bibliographic and chemical identity data.
When does US 12,122,789 lose exclusivity in the US?
Answer: No expiration date is derivable from the claim text. Expiry depends on the patent’s filing date, prosecution history, and any term adjustments. No defensible timing can be stated from the information provided.
What generic or biosimilar entry risks does this create?
Answer: This is an API solid-form patent, so the key risk is “Form A knock-on” by ANDA challengers and follow-on formulators.
ANDA-style risk mechanics
If an applicant submits an ANDA with the same drug substance but demonstrates that their solid is:
- still crystalline Form A (within the XRPD tolerance), then the patent can block approval or trigger Paragraph IV litigation leverage;
- a different polymorph/solvate not meeting the menu peak requirements, then design-around is more plausible; or
- a polymorph with overlapping peak locations that fails the required peak-count or subset anchors, then infringement can be contested on analytical grounds.
Evidence burden center
Most disputes on XRPD-defined polymorph patents turn on:
- instrument settings and radiation source (Cu Kα dependent claims),
- peak picking tolerance (±0.2°),
- sample preparation (grinding, hydration history),
- whether peaks “present” in the accused pattern are truly in the asserted list.
Key takeaways
- US 12,122,789 protects crystalline Form A of a “compound of formula (I)” defined primarily by XRPD peak positions with ±0.2° tolerance.
- Claim 1 is the breadth engine: at least two XRPD peaks from a defined set.
- Dependent claims tighten identity through (a) additional peak-count requirements, (b) specific peak lists, (c) optional Cu Kα source limitation, and (d) corroborating IR/Raman and DSC melting point constraints.
- Protection extends beyond API to pharmaceutical compositions (including powder) and a kit that constitutes into an oral aqueous solution using water.
- Enforcement leverage is built into the claim hierarchy: broad XRPD menu claims plus narrow enumerated fallbacks provide multiple litigation angles depending on the accused product’s solid-state analytics.
FAQs
-
Can an accused solid avoid infringement by using a different radiation source than Cu Kα?
The XRPD source limitation is explicit in certain dependent claims (e.g., Claim 3; Claims 22–23). Independent/menu XRPD claims are not explicitly limited to Cu Kα in the provided text, so source-based design-around is partial at best.
-
Does Claim 1 require the accused XRPD pattern to match exactly, or only to contain the claimed peaks?
The claim language uses “comprising” and “at least two XRPD peaks,” so it is directed to containing the required peaks, not an exclusivity of the full pattern.
-
How do the IR and Raman peak claims affect infringement analysis?
They provide additional identity markers that can confirm Form A when XRPD alone is ambiguous, and they can also be used to rebut a polymorph defense.
-
Do the composition and kit claims require a specific dosage form beyond “powder” and oral constitution?
The claims provided include powder (Claim 10) and a kit for constitution into oral aqueous solution (Claim 11), but they still rely on the presence of the patented solid form.
-
Are other polymorphs or hydrates automatically outside the patent?
Not automatically. If another form still shows the required XRPD peaks within the stated tolerances and matches Form A definitions, it can still fall within the claims.
